Iambic sets $16 IPO price for $150 million offering
Iambic priced 9,375,000 shares at $16 on 14 October. Its announcement expected Nasdaq trading on 15 October and closing on 16 October.
Pricing confirmed
Iambic Therapeutics announced its IPO price on 14 October 2026: $16 per share for 9,375,000 shares. The final prospectus confirms those terms and approval to list on the Nasdaq Global Select Market under IAM. The base offering represents $150 million before fees and expenses.
All shares are being offered by the company. The underwriters also received a 30-day option for 1,406,250 additional shares. Iambic's announcement expected trading to begin on 15 October and expected the offering to close on 16 October, subject to customary conditions. Those dates describe the announced timetable; this update does not confirm settlement.
What investors are funding
Iambic combines AI models with automated chemistry and biology experiments to develop medicines. Its prospectus says the platform has not yet produced an approved drug. That leaves clinical execution central to the investment case.
The prospectus lists $10.5 million in underwriting discounts and commissions, leaving $139.5 million before other expenses. The $150 million headline is therefore gross offering proceeds, not net cash available to fund the business.